The first oral glucagon-like peptide-1 for obesity is now available in the United States following its approval by the Food and Drug Administration in December
Yes, adverse effects may include pain, redness, or swelling at the injection site
It is also worth considering that fatigue attributed to GLP-1 therapy may actually reflect underlying conditions such as hypothyroidism, anemia, sleep apnea, or depression, which should be evaluated if tiredness persists
BPC-157 (Body Protection Compound) is a synthetic peptide derived from a protective protein found in stomach acid, while TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide in the human body
And it's got a little kick, it's just a little spice
Yue Y, Huo F, Cheng F, Zhu X, Mafireyi T, Strongin RM, et al